The Fusion Paraflu assay, which detects and differentiates
Parainfluenza viruses, is the second diagnostic assay available on the Panther Fusion system, complementing the Panther Fusion Flu A/B/RSV assay.
(Quidel), USA) for influenza A virus, influenza B virus,
parainfluenza viruses types 1 to 4, respiratory syncytial virus, human metapneumovirus, and adenovirus, and an aliquot of each NPA was sent to Hong Kong Government Virus Laboratory, the Department of Health, for further testing by RT-PCR for detection of influenza A virus, influenza B virus,
parainfluenza viruses types 1 to 4, respiratory syncytial virus, adenovirus, and rhinovirus/enterovirus, as part of the routine clinical diagnostic protocol.
Seasonal distribution of human
parainfluenza virusesInfluenza viruses Influenza A (H3) virus 14 (7.9) 7 2013 Oct Influenza A(H1N1)pdm09 virus 13 (7.3) 4 2014 May Influenza B virus 14 (7.9) 6 2014 May Other respiratory viruses Rhinovirus 35 (19.8) 10 2013 Oct
Parainfluenza viruses 1-4 5 (2.8) 1 NA Human metapneumovirus 4 (2.6) 2 2014 May Respiratory syncytial virus 4 (2.6) 1 NA (A and B) Enterovirus 1 (0.6) NA NA Adenovirus 1 (0.6) NA NA Bocavirus 0 NA NA Human CoVs Human CoV OC43 6 (3.4) 3 2014 Feb Human CoV 229E/NL63 2 (1.1) 1 NA MERS-CoV 0 NA NA Bacteria Chlamydophila pneumoniae 1 (0.6) NA NA Legionella spp.
Virologically confirmed population-based burden of hospitalization caused by respiratory syncytial virus, adenovirus, and
parainfluenza viruses in children in Hong Kong.
Parainfluenza viruses and RSV were observed most commonly between December and February (58% and 59%, respectively).
Schmidt, "Pathogenesis of acute respiratory illness caused by human
parainfluenza viruses," Current Opinion in Virology, vol.
Indirect immunofluorescence assays were negative for likely viruses including influenza A and B, respiratory syncytial virus, adenovirus, and
parainfluenza viruses types 1 to 3.
Human metapneumovirus is related to the respiratory syncytial virus, measles, mumps and
parainfluenza viruses. It infects people of all ages but is most common in children under five.
Prevention and treatment of respiratory syncytial virus and
parainfluenza viruses in immunocompromised patients.
United States Department of Health and Human Services (Washington, DC) has patented a chimeric
parainfluenza viruses (PIVs) that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.